Analysed KARYOPHARM THERAPEUTICS INC (KPTI:NASDAQ) News Sources
Karyopharm Therapeutics Inc (KPTI) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ...
14-05-2026
yahoo.com
Menarini Group Announces New Data at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
25-05-2026
yahoo.com
Karyopharm Therapeutics Teases ASCO SENTRY Data as FDA Path Comes Into Focus
26-05-2026
marketbeat.com
Karyopharm Therapeutics Spotlights Selinexor Milestones, ASCO Data and Cancer Trial Readouts
26-05-2026
marketbeat.com
Wall Street Analysts Think Karyopharm Therapeutics (KPTI) Could Surge 70.46%: Read This Before Placing a Bet
27-05-2026
yahoo.com
Karyopharm to Host Investor Conference Call Featuring Expert Perspectives on the Phase 3 SENTRY Trial in Myelofibrosis Following 2026 ASCO Presentation
01-06-2026
yahoo.com
Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
01-06-2026
yahoo.com
Karyopharm to Present Results from Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis in Late-Breaking Oral Presentation at ASCO 2026 with Simultaneous Publication in the Journal of Clinical Oncology
02-06-2026
yahoo.com
What is the current price of KARYOPHARM THERAPEUTICS INC (KPTI:NASDAQ)?
The current price of KARYOPHARM THERAPEUTICS INC (KPTI:NASDAQ) is $8.8.
KARYOPHARM THERAPEUTICS INC (KPTI:NASDAQ) absolute price change since previous trading day?
The absolute price change of KARYOPHARM THERAPEUTICS INC (KPTI:NASDAQ) since the previous trading day is $-1.02.
KARYOPHARM THERAPEUTICS INC (KPTI:NASDAQ) percentage price change since previous trading day?
The percentage price change of KARYOPHARM THERAPEUTICS INC (KPTI:NASDAQ) since the previous trading day is -10.387%.
What is the most recent average sentiment score for KARYOPHARM THERAPEUTICS INC (KPTI:NASDAQ)?
The most recent average sentiment score for KARYOPHARM THERAPEUTICS INC (KPTI:NASDAQ) is 73 out of 100.
What is the most recent average sentiment for KARYOPHARM THERAPEUTICS INC (KPTI:NASDAQ)?
The most recent sentiment for KARYOPHARM THERAPEUTICS INC (KPTI:NASDAQ) is .
SEC-8K** Filing Available For KARYOPHARM THERAPEUTICS INC (KPTI:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.